Holen Sie sich die Stockscreener-App
60.62
0.28%
-0.155
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$60.77
Offen:
$60.94
24-Stunden-Volumen:
4.45M
Relative Volume:
0.32
Marktkapitalisierung:
$123.38B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
17.53
EPS:
3.4587
Netto-Cashflow:
$15.30B
1W Leistung:
+8.23%
1M Leistung:
+8.48%
6M Leistung:
+31.88%
1J Leistung:
+9.13%
1-Tages-Spanne:
$59.95
$61.45
1-Wochen-Bereich:
$56.43
$62.05
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.60 | 123.71B | 48.19B | 7.06B | 15.30B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,031.92 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.66 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
224.56 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
158.42 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.78 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance Singapore
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim - StreetInsider
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Finviz
Bristol Myers Squibb stock gets positive readthrough from Bayer stroke data - Investing.com
Bristol-Myers Squibb (BMY) Exceeds Q4 Earnings Expectations - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations, Sets Stron - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Q4, Projects Robust Gr - GuruFocus
Why Bristol Myers Squibb Stock Topped the Market Today - Yahoo Finance
Bristol Myers (BMY) Maintains Positive Outlook Amid Stroke Treat - GuruFocus
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target - TipRanks
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ... By GuruFocus - Investing.com Canada
Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat - morningstar.com
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations and Raises Dividend - GuruFocus
Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. - Barron's
We're increasing our price target on Bristol Myers after earnings and guidance top forecasts - CNBC
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. - Barron's
Bristol-Myers Squibb Q4 2025 slides: Growth portfolio offsets legacy declines - Investing.com
Bristol Myers posts modest Q4 growth, outlines cautious outlook - The Pharma Letter
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts By Investing.com - Investing.com India
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts - Investing.com
Bristol’s Outlook Tops Views as New Drugs Gain Momentum - bloomberg.com
Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance - MarketBeat
Bristol Myers earnings beat amid blood thinner, cancer immunotherapy strength - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025 - Finviz
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook - Chartmill
Bristol Myers: Q4 Earnings Snapshot - kens5.com
Bristol Myers earnings beat estimates amid cancer immunotherapy drug strength - Investing.com
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.79%
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):